Endoscopic gallbladder stenting reduces recurrent cholecystitis in deferred cholecystectomy patients

Endoscopic gallbladder stenting (ETGS) significantly reduces recurrent cholecystitis in patients with deferred cholecystectomy, demonstrating 0% recurrence at 3 months compared to 18.3% in the non-ETGS group. Although not statistically significant, ETGS also shows a trend towards lower recurrence (0% vs. 10%) at 3-6 months. Technical and clinical success rates for ETGS are 90% and 100%, respectively, highlighting its efficacy in preventing cholecystitis. Results suggest ETGS’s potential as an adjunctive treatment in acute cholecystitis with common bile duct stones.